The company claims that by using a single log-in, sponsors and end-users have faster access to their clinical data and MRI images through a streamlined and secure process within a CRF 21 Part 11 compliant system. To ensure proper security and confidentiality, I-Vault 2.3 offers an audit trail that enables sponsors to monitor and identify file uploads and all user activity.

The availability of a consolidated solution would allow sponsors to better monitor and analyze all clinical trial data, leading to increased transparency and efficiencies and cost savings.

James DeSanti, founder and chief executive officer of PharmaVigilant, said: “Our clients are looking to us to incorporate imaging technology into our product suite so they can consolidate all of their trial information within one solution. We are currently seeing the industry moving toward a rapid consolidation of technologies into single solutions to better streamline the drug development process and control costs.

“Only companies with the flexibility to make strategic adjustments and the ability to make noteworthy investments in their products will be ready to meet this growing demand from sponsors. PharmaVigilant clearly meets these requirements as seen in our newest release of I-Vault 2.3, and we are positioned to lead the market in the coming years with our integrated and game-changing solutions.”